Trial
NCT03205995
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Omeros Corporation
Collaborators
—
Condition
Thrombotic Microangiopathies
Intervention
OMS721 (narsoplimab)
Why stopped
Sponsor terminated study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-10